scholarly journals The Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer at a Canadian Academic Center: A Retrospective Chart Review

2021 ◽  
Vol 28 (6) ◽  
pp. 4247-4255
Author(s):  
Goulnar Kasymjanova ◽  
Aksa Anwar ◽  
Victor Cohen ◽  
Khalil Sultanem ◽  
Carmela Pepe ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Radiation Treatment ◽  
Lung Cancer Surgery ◽  
Retrospective Chart Review ◽  
Diagnosis And Treatment ◽  
Definitive Treatment ◽  
Cancer Center ◽  
Lung Cancer Patients ◽  
The Impact

The large burden of COVID-19 on health care systems worldwide has raised concerns among medical oncologists about the impact of COVID-19 on the diagnosis and treatment of lung cancer patients. In this retrospective cohort study, we investigated the impact of COVID-19 on lung cancer diagnosis and treatment before and during the COVID-19 era. New lung cancer diagnoses decreased by 34.7% during the pandemic with slightly more advanced stages of disease, there was a significant increase in the utilization of radiosurgery as the first definitive treatment, and a decrease in both systemic treatment as well as surgery compared to the pre-COVID-19 era. There was no significant delay in starting chemotherapy and radiation treatment during the pandemic compared to pre-COVID-19 time. However, we observed a delay to lung cancer surgery during the pandemic time. COVID-19 seems to have had a major impact at our lung cancer center on the diagnoses and treatment patterns of lung cancer patients. Many oncologists fear that they will see an increase in newly diagnosed lung cancer patients in the coming year. This study is still ongoing and further data will be collected and analyzed to better understand the total impact of the COVID-19 pandemic on our lung cancer patient population.

scholarly journals Multidisciplinary care models for patients with lung cancer

Breathe ◽  
2020 ◽  
Vol 16 (4) ◽  
pp. 200076
Author(s):  
Georgia Hardavella ◽  
Armin Frille ◽  
Christina Theochari ◽  
Elli Keramida ◽  
Elena Bellou ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Lung Cancer Surgery ◽  
Multidisciplinary Care ◽  
Cancer Outcomes ◽  
Care Model ◽  
Team Members ◽  
Lung Cancer Patients ◽  
Roles And Responsibilities ◽  
The Impact

Multidisciplinary care is the cornerstone of lung cancer treatment in the developed world, even though there is a relative lack of consistent evidence that this care model improves outcomes. In this review, we present the available literature regarding how to set up and run an efficient multidisciplinary care model for lung cancer patients with emphasis on team members’ roles and responsibilities. Moreover, we present some limited evidence about multidisciplinary care and its impact on lung cancer outcomes and survival.This review provides simple guidance on setting up and running a multidisciplinary service for lung cancer patients. It highlights the importance of defined roles and responsibilities for team members. It also presents concise information based on the literature regarding the impact of multidisciplinary care in lung cancer outcomes (e.g. survival of patients undergoing lung cancer surgery).

Improving hematology/oncology clinical research recruitment via universal prescreening: The VA Connecticut (VACT) Cancer Center experience.

2021 ◽  
Vol 39 (28_suppl) ◽  
pp. 79-79
Author(s):  
Jenny Jing Xiang ◽  
Alicia Roy ◽  
Christine Summers ◽  
Monica Delvy ◽  
Jessica Lee O'Donovan ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Clinical Trials ◽  
Clinical Research ◽  
Cancer Patients ◽  
Cancer Center ◽  
Cancer Type ◽  
Eligibility Criteria ◽  
Research Recruitment ◽  
Lung Cancer Patients ◽  
Study Enrollment

79 Background: Patient-trial matching is a critical step in clinical research recruitment that requires extensive review of clinical data and trial requirements. Prescreening, defined as identifying potentially eligible patients using select eligibility criteria, may streamline the process and increase study enrollment. We describe the real-world experience of implementing a standardized, universal clinical research prescreening protocol within a VA cancer center and its impact on research enrollment. Methods: An IRB approved prescreening protocol was implemented at the VACT Cancer Center in March 2017. All patients with a suspected or confirmed diagnosis of cancer are identified through tumor boards, oncology consults, and clinic lists. Research coordinators perform chart review and manually enter patient demographics, cancer type and stage, and treatment history into a REDCap (Research Electronic Data Capture) database. All clinical trials and their eligibility criteria are also entered into REDCap and updated regularly. REDCap generates real time lists of potential research studies for each patient based on his/her recorded data. The primary oncologist is alerted to a patient’s potential eligibility prior to upcoming clinic visits and thus can plan to discuss clinical research enrollment as appropriate. Results: From March 2017 to December 2020, a total of 2548 unique patients were prescreened into REDCAP. The mean age was 71.5 years, 97.5% were male, and 15.5% were African American. 32.57 % patients had genitourinary cancer, 17.15% had lung cancer, and 46.15% were undergoing malignancy workup. 1412 patients were potentially eligible after prescreening and 556 patients were ultimately enrolled in studies. The number of patients enrolled on therapeutic clinical trials increased after the implementation of the prescreening protocol (35 in 2017, 64 in 2018, 78 in 2019, and 55 in 2020 despite the COVID19 pandemic). Biorepository study enrollment increased from 8 in 2019 to 15 in 2020. The prescreening protocol also enabled 200 patients to be enrolled onto a lung nodule liquid biopsy study from 2017 to 2019. Our prescreening process captured 98.57% of lung cancer patients entered into the cancer registry during the same time period. Conclusions: Universal prescreening streamlined research recruitment operations and was associated with yearly increases in clinical research enrollment at a VA cancer center. Our protocol identified most new lung cancer patients, suggesting that, at least for this malignancy, potential study patients were not missed. The protocol was integral in our program becoming the top accruing VA site for NCI’s National Clinical Trial Network (NCTN) studies since 2019.

Mood disorders and outcomes in lung cancer patients undergoing surgery: a brief summery

2020 ◽  
Author(s):  
Maria Salvina Signorelli ◽  
Teresa Surace ◽  
Marcello Migliore ◽  
Eugenio Aguglia
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Mood Disorders ◽  
Psychiatric Symptoms ◽  
Depression And Anxiety ◽  
Lung Cancer Patients ◽  
Patients With Cancer ◽  
Treatment Of Depression ◽  
The Impact

Cancer is a leading cause of death worldwide. Literature reports depression and anxiety are the most common psychiatric symptoms in cancer patients. Notably, lung cancer is associated with major depressive disorder in 5–13% of cases. The present article aims to give an overview regarding the impact of mood disorders on the outcomes of patients affected by lung cancer. Our review showed that pharmacological treatment and psychotherapy can be useful to improve the quality of life of patients with lung cancer. Moreover, the treatment of depression and anxiety can be associated with a reduced mortality. In conclusion, it is important to consider psychiatric care as important as other adjuvant oncologic therapies in patients with cancer.

scholarly journals P1-279: The impact of bisphosphonates therapy in survival of lung cancer patients with bone metastasis

2007 ◽  
Vol 2 (8) ◽  
pp. S850-S851
Author(s):  
Kostas Zarogoulidis ◽  
Efimia Boutsikou ◽  
Theodoros Kontakiotis ◽  
Klio Eleftheriou ◽  
Ellada Eleftheriadou ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Bone Metastasis ◽  
Cancer Patients ◽  
Lung Cancer Patients ◽  
The Impact

The pathway to diagnosis and treatment for surgically managed lung cancer patients

2019 ◽  
Author(s):  
Victoria White ◽  
Rebecca J Bergin ◽  
Robert J Thomas ◽  
Kathryn Whitfield ◽  
David Weller
Keyword(s):  
Lung Cancer ◽  
Primary Care ◽  
Cancer Patients ◽  
Secondary Care ◽  
Primary Care Physicians ◽  
Treatment Time ◽  
Early Stage ◽  
Diagnosis And Treatment ◽  
Early Stage Disease ◽  
Lung Cancer Patients

Abstract Background Most lung cancer is diagnosed at an advanced stage, resulting in poor survival. This study examined diagnostic pathways for patients with operable lung cancer to identify factors contributing to early diagnosis. Methods Surgically treated lung cancer patients (aged ≥40, within 6 months of diagnosis), approached via the population-based Cancer Registry, with their primary care physicians (PCPs) and specialists completed cross-sectional surveys assessing symptoms, diagnostic route (symptomatic or ‘investigation’ of other problem), tests, key event dates and treatment. Time intervals to diagnosis and treatment were determined, and quantile regression examined differences between the two diagnostic routes. Cox proportional hazard regression analyses examined associations between survival and diagnostic route adjusting for stage, sex and age. Results One hundred and ninety-two patients (36% response rate), 107 PCPs and 55 specialists participated. Fifty-eight per cent of patients had a symptomatic diagnostic route reporting an average of 1.6 symptoms, most commonly cough, fatigue or haemoptysis. Symptomatic patients had longer median primary care interval than ‘investigation’ patients (12 versus 9 days, P < 0.05) and were more likely to report their PCP first-ordered imaging tests. Secondary care interval was shorter for symptomatic (median = 43 days) than investigation (median = 62 days, P < 0.05) patients. However, 56% of all patients waited longer than national recommendations (6 weeks). While survival estimates were better for investigation than symptomatic patients, these differences were not significant. Conclusion Many operable lung cancer patients are diagnosed incidentally, highlighting the difficulty of symptom-based approaches to diagnosing early stage disease. Longer than recommended secondary care interval suggests the need for improvements in care pathways.

Systematic intrafraction shifts of mediastinal lymph node targets between setup imaging and radiation treatment delivery in lung cancer patients

2018 ◽  
Vol 126 (2) ◽  
pp. 318-324 ◽  
Author(s):  
Mai Lykkegaard Schmidt ◽  
Lone Hoffmann ◽  
Ditte S. Møller ◽  
Marianne Marquard Knap ◽  
Torben Riis Rasmussen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lymph Node ◽  
Cancer Patients ◽  
Radiation Treatment ◽  
Mediastinal Lymph Node ◽  
Treatment Delivery ◽  
Lung Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document